Research integrates organoids and extracellular vesicles to identify biomarkers in Alzheimer's disease, suggesting a new approach for treatment evaluation.
Integrating organoid and EV data provides a systems-level view of AD pathophysiology and treatment response, positioning this dual-platform model as a cost-effective tool for precision medicine and drug discovery.
No takes yet. Share an insight, caveat, or question.
Boyd et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: